CROMSOURCE, an international full service contract research organization (CRO), today announced the official opening of new office premises in Paris, France.
CROMSOURCE, an international full service contract research organization (CRO), today announced the official opening of new office premises in Paris, France.
‘CROMSOURCE continues to grow successfully as a result of our unique commitment to deliver our clients’ projects on time, on budget and to the highest quality’, noted Oriana Zerbini, CEO of CROMSOURCE. ‘As a result we needed to increase our presence in France, and I am delighted to announce that we have done this through expansion of our team and the opening of new office premises.’
‘With more than 33% of international phase II and III studies being performed here, France is a key strategic country for CROMSOURCE’, said Christian Milla, Global Head of the Medical Division and Director of Operations, France. Christian is based in the new offices, which are located on the Left Bank area of Paris, close to the University of Sciences and the Paris Biopark. ‘We have been growing our activity here year on year, and we look forward to further growth in this region in years to come. With our intense client focus, comprehensive service portfolio and international reach we are a perfect development partner for the vibrant life sciences industry in France. Being on the French Ministry of Research (FMR) list of approved CROs also means that many of our clients can claim significant tax credits for R&D activities executed by CROMSOURCE on their behalf.’
Margherita Mosconi, Director of Client Project Development, added ‘There is a high demand in France from smaller biopharmaceutical and medical technology companies for knowledgeable partners who can support them and keep within timelines and budgets. These clients appreciate the CROMSOURCE philosophy of acting as an expert addition to their team. We leverage our expertise to propose the optimal approach to each of their projects. Uniquely, we then guarantee to deliver the plan to the highest quality, on time and on budget.’
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.